Junyan Zeng1, Jie Liu2, Qiumin Qu2, Xiongfei Zhao3, Jie Zhang4. 1. Department of Neurology, Dongpo District, Meishan Cardio Cerebrovascular Disease Hospital, No.66, West Third Section of Qitong Road, Meishan, 620010, China. 2. Department of Neurology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. 3. Department of Neurology, Dongpo District, Meishan Cardio Cerebrovascular Disease Hospital, No.66, West Third Section of Qitong Road, Meishan, 620010, China. feizhuang7350@163.com. 4. Department of Neurology, Dongpo District, Meishan Cardio Cerebrovascular Disease Hospital, No.66, West Third Section of Qitong Road, Meishan, 620010, China. zhangmuqiefei@163.com.
Abstract
BACKGROUND: JNK pathway-associated phosphatase (JKAP) is engaged in Alzheimer's disease (AD) pathology via regulating immune response, cluster of differentiation 4 positive (CD4+) T cell differentiation, inflammation, and phosphorylated tau (p-tau). This study aimed to investigate its clinical value serving as a biomarker for AD. METHODS: Fifty AD patients, 50 Parkinson's disease (PD) patients, and 50 controls (patients with non-degenerative neurological diseases with normal cognition) were enrolled. Their β-protein 42 (Aβ42), total tau (t-tau), p-tau, and Mini-Mental State Examination (MMSE) scale were assessed. Furthermore, JKAP in serum and T-help type 1 (Th1) and T-help type 17 (Th17) cells in CD4+ T cells were measured. RESULTS: JKAP level was lower, while Th17 cell proportion (but not Th1 cell proportion) was higher in AD patients compared with PD patients and controls (all P < 0.01). Besides, JKAP level negatively correlated with both Th1 (r = - 0.306, P = 0.030) and Th17 (r = - 0.380, P = 0.006) cell proportions in AD patients but not PD patients and controls. Furthermore, in AD patients, JKAP positively correlated with Aβ42 (r = 0.307, P = 0.030) and MMSE score (r = 0.350, P = 0.013) while negatively correlated with p-tau (r = - 0.280, P = 0.048); Th17 cell proportion negatively associated with Aβ42 (r = - 0.281, P = 0.048) and MMSE score (r = - 0.366, P = 0.009). Notably, JKAP was negatively related to 1-year (r = - 0.297, P = 0.038) and 2-year MMSE decline (r = - 0.304, P = 0.048); Th17 cell proportion was positively linked with 1-year (r = 0.392; P = 0.008), 2-year (r = 0.482, P = 0.001), and 3-year (r = 0.365, P = 0.013) MMSE decline. CONCLUSION: JKAP, Th1 cells, and Th17 cells are dysregulated and inter-correlated; among them, JKAP and Th17 cells relate to cognitive impairment progression in AD patients.
BACKGROUND: JNK pathway-associated phosphatase (JKAP) is engaged in Alzheimer's disease (AD) pathology via regulating immune response, cluster of differentiation 4 positive (CD4+) T cell differentiation, inflammation, and phosphorylated tau (p-tau). This study aimed to investigate its clinical value serving as a biomarker for AD. METHODS: Fifty AD patients, 50 Parkinson's disease (PD) patients, and 50 controls (patients with non-degenerative neurological diseases with normal cognition) were enrolled. Their β-protein 42 (Aβ42), total tau (t-tau), p-tau, and Mini-Mental State Examination (MMSE) scale were assessed. Furthermore, JKAP in serum and T-help type 1 (Th1) and T-help type 17 (Th17) cells in CD4+ T cells were measured. RESULTS: JKAP level was lower, while Th17 cell proportion (but not Th1 cell proportion) was higher in AD patients compared with PD patients and controls (all P < 0.01). Besides, JKAP level negatively correlated with both Th1 (r = - 0.306, P = 0.030) and Th17 (r = - 0.380, P = 0.006) cell proportions in AD patients but not PD patients and controls. Furthermore, in AD patients, JKAP positively correlated with Aβ42 (r = 0.307, P = 0.030) and MMSE score (r = 0.350, P = 0.013) while negatively correlated with p-tau (r = - 0.280, P = 0.048); Th17 cell proportion negatively associated with Aβ42 (r = - 0.281, P = 0.048) and MMSE score (r = - 0.366, P = 0.009). Notably, JKAP was negatively related to 1-year (r = - 0.297, P = 0.038) and 2-year MMSE decline (r = - 0.304, P = 0.048); Th17 cell proportion was positively linked with 1-year (r = 0.392; P = 0.008), 2-year (r = 0.482, P = 0.001), and 3-year (r = 0.365, P = 0.013) MMSE decline. CONCLUSION: JKAP, Th1 cells, and Th17 cells are dysregulated and inter-correlated; among them, JKAP and Th17 cells relate to cognitive impairment progression in AD patients.